跳至主要内容
临床试验/2023-504641-32-00
2023-504641-32-00撤回2 期

A geroscience approach to post-acute COVID-19 syndrome (PACS) by Diet and Exercise plus rapamycin or metformin to treat Frailty and restore immune functions: a randomized, single center clinical trial.

Azienda Ospedaliero Universitaria Di Modena1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年7月13日最近更新:

试验速览

阶段
2 期
状态
撤回
发起方
入组人数
60
试验地点
1
主要终点
Short Physical Performance Battery

研究概览

简要总结

The AIM 1 of the project is to compare two years lifestyles intervention alone or in association with metformin or rapamycin pulse therapy in changing aging trajectories depicted by by an improvement of physical performance assessed by SPPB score as continous variable in people with PACS.

研究设计

分配方式
Randomized
主要目的
Gero-pacs
盲法
None

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Confirmed PACS diagnosis according to WHO definition by two consecutive clinical assessment
  • Previous hospital admission for Severe COVID Pneumonia
  • Age 40-80 years
  • Frailty or pre-frailty status performed with frailty phenotype criteria
  • Independently mobile
  • Able and willing to provide written consent.

排除标准

  • Previous or current use of metformin
  • Diabetes history or diagnosis at baseline
  • Transplant or cancer requiring chemotherapy
  • History of chronic kidney disease (eGFR<30 mil/min)
  • Allergies to metformin or rapamycin
  • Female participant pregnant or breastfeeding
  • Baseline SPPB score <3
  • Life expectancy <6 months

结局指标

主要结局

Short Physical Performance Battery

Short Physical Performance Battery

Frailty reversibility

Frailty reversibility

Quality of life assessed with EQ 5D-5L

Quality of life assessed with EQ 5D-5L

次要结局

  • Identification of the main changes in peripheral blood cells that identify the immune risk phenotype (CD4/CD8 T cell ratio, senescent/activated CD8+ T cells, number of B lymphocytes and NK cells)
  • Evaluation of the change that occur in the plasma level of the main inflammatory and anti-inflammatory cytokines, chemokines and their receptors.
  • Analysis of the differences in monocyte activation and phenotypes (inflammatory, classical, non classical) among groups
  • The occurrence of adverse events (AEs), changes on clinical examination including vital signs and weight, and laboratory examinations (biochemistry, hematology and urinalysis)

研究者

发起方
Azienda Ospedaliero Universitaria Di Modena
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Giovanni Guaraldi

Scientific

Azienda Ospedaliero Universitaria Di Modena

研究点 (1)

Loading locations...

相似试验